Medical technology giant Medtronic (NYSE:MDT）RecentlyAnnounce,Its latest generation of automatic insulin delivery (AID) SystemMiniMed 780GHave obtainedCELogo certification, expanded indications to2Type diabetes patients,2Years and above1Children with type diabetes and patients with gestational diabetes.This certification marks a significant expansion in the application of the device within the European market, while also paving the way for the company’s planned spin-off into an independent diabetes business.MiniMedLay the technical milestone.

MiniMed 780GThe system integratesSimplera SyncContinuous Glucose Monitoring (CGM) technology, which enables the automatic adjustment of basal insulin and mealtime insulin, correcting blood glucose levels every five minutes. The system optimizes postprandial blood glucose management through a meal detection algorithm, significantly reducing the need for user manual intervention.

This timeCECertification makesMiniMed 780GBecoming the first in Europe to be approved for2Type diabetesAIDSystem.SupportClinicalData includes:

• 2Clinical Trial for Type Diabetes Patients:

95Example2Data from patients with type diabetes show that after system use, glycosylated hemoglobin (HbA1c) Average reduction0.7%, Time in Range (70-180 mg/dL) Increase to80%, Hypoglycemia (<54 mg/dL) Time is less than0.5%。

Real-World Evidence:26,427Example2Type patient analysis shows that the average range time exceeds70%(International Consensus Target), the incidence of severe hypoglycemia is less than1%. The system is still in the United States at present2Type diabetes indication approval stage, Medtronic is working withFDAClose Communication on Submission of Materials.

• Data Support for Young Children's Applications

ThroughLENNYTest (2-6Year1Children with type 1 diabetes), automatic mode achieves compared to manual mode:

HbA1cReduce0.6%

Extended Time Range9.9%

United KingdomNHSand the German Diabetes Association hasAIDSystem Incorporates Pediatric Care Standards Recommendations. British Pediatric EndocrinologistFiona CampbellDoctor's Evaluation:"This technology reduces the burden of home monitoring, supports children's healthy development, and is a key transformation in quality of life."

• Innovation in Gestational Blood Sugar Management

During Pregnancy1For patients with type diabetes, the system can set a lower blood glucose target (≤100 mg/dL), European studies show:

Strict Range Time Reached66.5%(Traditional Treatment Significantly Improved)

Reduction in nocturnal hypoglycemia, increase in treatment satisfaction

The result is in line with international guidelines for pregnancy.AIDRecommended for use.

Previously,InsuletTheOmnipod 5（2024Year8Month) andTandem Diabetes Care（2025Year2Month) successively obtainedFDAApproved for use in2Type diabetes. Medtronic seizes the international market opportunity through European certification, with its full closed-loop algorithm andSimplera CGMThe integration advantage may become a differentiated competitiveness.

MiniMed 780GThe expansion of indications reflectsAIDTechnology from1Type diabetes is showing a trend of spreading to a broader population. With the accumulation of clinical evidence and the coverage of payment systems, automated insulin delivery is expected to become the new standard for diabetes management, providing precise solutions for patients' health throughout their entire life cycle.